A 52-year-old man presents with sudden-onset fever (39.2°C), burning erythema, and hundreds of pinpoint non-follicular sterile pustules on the face and intertriginous areas 48 hours after starting amoxicillin-clavulanate for a dental abscess. CBC shows WBC 18,000 with 88% neutrophilia; CRP 142 mg/L. Skin biopsy confirms subcorneal spongiform pustules with papillary dermal edema and mixed infiltrate. The diagnosis is Acute Generalized Exanthematous Pustulosis (AGEP). Which of the following management approaches marked **B** in the diagram is most appropriate for this patient?
A. Start long-term systemic immunosuppression to prevent recurrence
B. Admit to ICU for mandatory intensive monitoring and organ support
C. Initiate IV antifungals for fungal pustulosis
Stop the offending drug — disease is self-limited and resolves with desquamation
D.
Explanation
Why "Stop the offending drug — disease is self-limited and resolves with desquamation" is right
AGEP is a CD4/CD8 T-cell-mediated drug reaction characterized by rapid onset (typically <4 days for antibiotics), high fever, neutrophilic leucocytosis, and subcorneal/intraepidermal spongiform pustules on histology. The cornerstone of management is identification and immediate discontinuation of the culprit drug (amoxicillin-clavulanate in this case). The disease is self-limited and resolves spontaneously over 1–2 weeks with characteristic generalized post-pustular desquamation. Systemic steroids are not routinely required because the condition resolves without them. Supportive care (paracetamol, emollients, mid-potency topical steroids) is sufficient for most cases. This patient has no oral/genital erosions, no facial edema, and no organomegaly—features that would warrant systemic steroids only if severe mucous membrane involvement or extensive systemic symptoms were present (Sidoroff EuroSCAR, J Cutan Pathol 2001; Roujeau, BJD 1991).
Why each distractor is wrong
Initiate IV antifungals for fungal pustulosis: AGEP is a drug-induced T-cell-mediated reaction, not a fungal infection. The sterile pustules, absence of fungal culture, and clinical context of recent antibiotic exposure make fungal pustulosis implausible. IV antifungals are unnecessary and delay appropriate management.
Admit to ICU for mandatory intensive monitoring and organ support: ICU admission is not mandatory for AGEP. This patient has no organ dysfunction, no mucous membrane erosions, and no systemic complications. AGEP has a mortality <5%, typically only in patients with comorbidities or secondary infection. Routine supportive care in an outpatient or general ward setting is adequate.
Start long-term systemic immunosuppression to prevent recurrence: AGEP rarely recurs unless the patient is rechallenged with the offending drug. Long-term immunosuppression is not indicated and exposes the patient to unnecessary toxicity. Once the drug is stopped and the diagnosis is documented, reassurance and allergy avoidance are appropriate.
High-YieldNEET PG
AGEP = rapid-onset T-cell drug reaction with sterile pustules and neutrophilia; management is stop the drug + supportive care; it resolves spontaneously in 1–2 weeks without systemic steroids.
